Amevive alefacept recombinant human LFA-3 fusion protein regulatory update

The FDA granted marketing approval for Amevive to treat adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. In double-blind, placebo-controlled Phase III trials in more than 1,000 patients with moderate to severe plaque psoriasis, Amevive met the primary endpoint of a 75% reduction of psoriasis area and severity index (PASI) score. ...